HK1221646A1 - 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 - Google Patents
高劑量普利多匹定用於治療亨廷頓舞蹈症的用途Info
- Publication number
- HK1221646A1 HK1221646A1 HK16109788.9A HK16109788A HK1221646A1 HK 1221646 A1 HK1221646 A1 HK 1221646A1 HK 16109788 A HK16109788 A HK 16109788A HK 1221646 A1 HK1221646 A1 HK 1221646A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating
- high dose
- huntingtons disease
- dose pridopidine
- pridopidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US201361877832P | 2013-09-13 | 2013-09-13 | |
| PCT/US2014/043204 WO2014205229A1 (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1221646A1 true HK1221646A1 (zh) | 2017-06-09 |
Family
ID=52105289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16109788.9A HK1221646A1 (zh) | 2013-06-21 | 2016-08-16 | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (zh) |
| EP (1) | EP3010506B1 (zh) |
| JP (1) | JP2016523862A (zh) |
| KR (1) | KR102316933B1 (zh) |
| CN (1) | CN105592848A (zh) |
| AU (1) | AU2014281414A1 (zh) |
| BR (1) | BR112015029918A2 (zh) |
| CA (1) | CA2913781C (zh) |
| CL (1) | CL2015003690A1 (zh) |
| DK (1) | DK3010506T3 (zh) |
| EA (1) | EA201690069A1 (zh) |
| ES (1) | ES2879631T3 (zh) |
| HK (1) | HK1221646A1 (zh) |
| HU (1) | HUE054783T2 (zh) |
| IL (1) | IL242804B (zh) |
| MX (1) | MX2015017307A (zh) |
| PE (2) | PE20170302A1 (zh) |
| PH (1) | PH12015502691A1 (zh) |
| PL (1) | PL3010506T3 (zh) |
| SG (1) | SG11201509729YA (zh) |
| TW (1) | TW201529069A (zh) |
| UA (1) | UA122999C2 (zh) |
| UY (1) | UY35624A (zh) |
| WO (1) | WO2014205229A1 (zh) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| ES2911800T3 (es) * | 2014-01-22 | 2022-05-20 | Prilenia Neurotherapeutics Ltd | Formulaciones de liberación modificada de pridopidina |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US10603311B2 (en) * | 2015-02-25 | 2020-03-31 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| WO2017015615A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA3015512C (en) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| EP3503890A4 (en) * | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA |
| WO2018039477A1 (en) * | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating functional decline |
| JP2019529411A (ja) * | 2016-09-15 | 2019-10-17 | プリレニア ニューロセラピューティクス リミテッド | 不安症およびうつ病の治療のためのプリドピジンの使用 |
| CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
| WO2018136600A1 (en) | 2017-01-20 | 2018-07-26 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of fragile x syndrome |
| CA3072882C (en) * | 2017-08-14 | 2023-03-21 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
| AU2018326596B2 (en) * | 2017-08-30 | 2021-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| WO2019050775A1 (en) | 2017-09-08 | 2019-03-14 | Teva Pharmaceuticals International Gmbh | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
| EA202193190A1 (ru) * | 2019-06-12 | 2022-03-24 | Прилиния Ньюротерапьютикс Лтд. | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов |
| JP7432711B2 (ja) * | 2019-09-17 | 2024-02-16 | エフ． ホフマン－ラ ロシュ アーゲー | 動作障害患者に対する個別化医療の改善 |
| WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EP1713486A4 (en) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
| CN101056854B (zh) | 2004-10-13 | 2013-06-05 | Nsab神经研究瑞典公司分公司 | 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法 |
| EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| RU2470013C2 (ru) | 2007-04-12 | 2012-12-20 | НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе | N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов |
| WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| IN2015DN03219A (zh) | 2012-09-27 | 2015-10-02 | Teva Pharma | |
| AU2013323133A1 (en) | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease |
| ES2911800T3 (es) | 2014-01-22 | 2022-05-20 | Prilenia Neurotherapeutics Ltd | Formulaciones de liberación modificada de pridopidina |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| US10603311B2 (en) | 2015-02-25 | 2020-03-31 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| WO2018039477A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating functional decline |
| EP3503890A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA |
| JP2019529411A (ja) | 2016-09-15 | 2019-10-17 | プリレニア ニューロセラピューティクス リミテッド | 不安症およびうつ病の治療のためのプリドピジンの使用 |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
-
2014
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 MX MX2015017307A patent/MX2015017307A/es unknown
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en active Application Filing
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active IP Right Grant
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
-
2016
- 2016-08-16 HK HK16109788.9A patent/HK1221646A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201509729YA (en) | 2015-12-30 |
| HUE054783T2 (hu) | 2021-09-28 |
| CN105592848A (zh) | 2016-05-18 |
| WO2014205229A1 (en) | 2014-12-24 |
| PE20170302A1 (es) | 2017-03-31 |
| UA122999C2 (uk) | 2021-02-03 |
| UY35624A (es) | 2015-01-30 |
| EP3010506A1 (en) | 2016-04-27 |
| DK3010506T3 (da) | 2021-07-12 |
| JP2016523862A (ja) | 2016-08-12 |
| EP3010506A4 (en) | 2017-02-08 |
| TW201529069A (zh) | 2015-08-01 |
| PL3010506T3 (pl) | 2021-11-02 |
| PH12015502691A1 (en) | 2016-03-14 |
| IL242804B (en) | 2022-02-01 |
| WO2014205229A8 (en) | 2015-04-09 |
| US20140378508A1 (en) | 2014-12-25 |
| US10322119B2 (en) | 2019-06-18 |
| CL2015003690A1 (es) | 2016-10-28 |
| EA201690069A1 (ru) | 2016-06-30 |
| KR102316933B1 (ko) | 2021-10-26 |
| CA2913781C (en) | 2022-05-10 |
| PE20160195A1 (es) | 2016-05-14 |
| BR112015029918A2 (pt) | 2017-07-25 |
| AU2014281414A1 (en) | 2016-01-21 |
| CA2913781A1 (en) | 2014-12-24 |
| KR20160055122A (ko) | 2016-05-17 |
| ES2879631T3 (es) | 2021-11-22 |
| EP3010506B1 (en) | 2021-05-12 |
| MX2015017307A (es) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221646A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| HK1225305A1 (zh) | 治療腦疾病的方法和組合物 | |
| IL241232B (en) | Cancer treatment agents | |
| EP2968348A4 (en) | COMPOUNDS FOR THE TREATMENT OF CANCER | |
| EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
| HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| IL244353A0 (en) | Compounds and use for cancer treatment | |
| HK1213817A1 (zh) | 治療癌症的方法 | |
| HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
| HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
| HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
| HK1219513A1 (zh) | 治療癌症的方法 | |
| HK1223547A1 (zh) | 癌症治療方法 | |
| GB201403083D0 (en) | Treatment of cancer | |
| EP2986294A4 (en) | COMPOUNDS FOR THE TREATMENT OF PAIN | |
| GB201308466D0 (en) | Improved process for treatment of minewater | |
| HK1232118A1 (zh) | 癌症的治療 | |
| GB201307348D0 (en) | Garment for therapeutic treatment | |
| HK1224215A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| EP2986295A4 (en) | COMPOUNDS FOR THE TREATMENT OF PAIN | |
| GB201321628D0 (en) | Treatment of disease | |
| GB201322347D0 (en) | Treatment of cancer |